FDA Clears Prescription Virtual Reality Therapeutic for Chronic Low Back Pain
The authorization was based on data from a randomized, double-blind study that evaluated the efficacy and safety of EaseVRx in 179 patients with chronic lower back pain.
The authorization was based on data from a randomized, double-blind study that evaluated the efficacy and safety of EaseVRx in 179 patients with chronic lower back pain.
Group-based CBT intervention produced modest, but sustained, reductions in measures of pain, pain-related disability
Using the programmer app, clinicians are able to remotely prescribe new treatment settings to the patient’s neuromodulation device via cloud and Bluetooth-based technology.
Patients will be able to share information collected in the app with health care providers to provide a comprehensive assessment of the SCS or DRG therapy.
The FDA reported that between July 27, 2016 and July 27, 2020, a total of 107,728 medical device reports (MDRs) associated with SCS devices intended for pain were received.
The FDA has approved an iOS-compatible app designed to work in tandem with Abbott’s neuromodulation technologies. The Company hopes the app will eliminate the need for patients to carry a separate programmer device and improve remote care.
Researchers assessed pain relief and functional improvement in patients receiving opioids for knee or hip osteoarthritis.
Treating osteoarthritis in older patients with tramadol vs nonsteroidal anti-inflammatory drugs may be associated with an increased mortality rate during the year following treatment initiation.